A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein-Reference-Cited by-同舟云学术

A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein

Published:2020-01-27 Issue:2 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

DeVincenzo John¹²,Tait Dereck³,Efthimiou John⁴,Mori Julie⁵,Kim Young-In¹²,Thomas Elaine³,Wilson Lynn³,Harland Rachel³,Mathews Neil³,Cockerill Stuart³,Powell Kenneth³,Littler Edward³

Affiliation:

1. University of Tennessee Center for Health Sciences, Memphis, Tennessee, USA

2. Children’s Foundation Research Institute at LeBonheur Children’s Hospital, Memphis, Tennessee, USA

3. ReViral Ltd., Stevenage, Hertfordshire, United Kingdom

4. Independent Respiratory Specialist, Oxford, United Kingdom

5. hVIVO Services Limited, London, United Kingdom

Abstract

Effective treatments for respiratory syncytial virus (RSV) infection are lacking. Here, we report a human proof-of-concept study for RV521, a small-molecule antiviral inhibitor of the RSV-F protein. In this randomized, double-blind, placebo-controlled trial, healthy adults were challenged with RSV-A Memphis-37b.

Funder

ReViral Ltd

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01884-19

Reference30 articles.

1. Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom

2. Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics

3. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

4. Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993–2008

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic Review of the Efficacy and Safety of RSV‐Specific Monoclonal Antibodies and Antivirals in Development;Reviews in Medical Virology;2024-08-29

2. Recent Progress toward the Discovery of Small Molecules as Novel Anti-Respiratory Syncytial Virus Agents;Journal of Medicinal Chemistry;2024-07-06

3. Spiro-Azetidine Oxindoles as Long-Acting Injectables for Pre-Exposure Prophylaxis against Respiratory Syncytial Virus Infections;Journal of Medicinal Chemistry;2024-06-27

4. Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein;Signal Transduction and Targeted Therapy;2024-06-10

5. Role of human challenge trials (HCTs) in drug development for respiratory syncytial virus (RSV);2024-05-24